| 000 | 01138 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515031907.0 | ||
| 264 | 0 | _c20060818 | |
| 008 | 200608s 0 0 eng d | ||
| 022 | _a1871-5273 | ||
| 024 | 7 |
_a10.2174/187152706777452245 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLewis, M M | |
| 245 | 0 | 0 |
_aD1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. _h[electronic resource] |
| 260 |
_bCNS & neurological disorders drug targets _cJun 2006 |
||
| 300 |
_a345-53 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDopamine Agonists _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 |
_aParkinson Disease _xphysiopathology |
| 650 | 0 | 4 |
_aReceptors, Dopamine D1 _xagonists |
| 700 | 1 | _aHuang, X | |
| 700 | 1 | _aNichols, D E | |
| 700 | 1 | _aMailman, R B | |
| 773 | 0 |
_tCNS & neurological disorders drug targets _gvol. 5 _gno. 3 _gp. 345-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/187152706777452245 _zAvailable from publisher's website |
| 999 |
_c16381287 _d16381287 |
||